In short
This article discusses the ongoing clinical trials of ABBV-916, a humanized IgG1 monoclonal antibody targeting N-terminally truncated pyroglutamate-3 Ab. The drug is being studied as a potential treatment for early Alzheimer's disease. The trials aim to evaluate the safety, efficacy, and effects of ABBV-916 on reducing amyloid plaques in the brain, which are associated with the progression of Alzheimer's disease.
At a glance
- Drug Name
- ABBV-916
- Drug Type
- Humanised IgG1 monoclonal antibody against N-terminally truncated pyroglutamate-3 Ab
- Target Condition
- Early Alzheimer's Disease
- Study Phase
- Phase 2
- Primary Objective
- Evaluate safety, tolerability, and amyloid reduction
- Administration
- Intravenous, once every four weeks
- Study Design
- Randomized, Double-Blind, Placebo-Controlled
- Study Duration
- 24-week treatment period, 16-week follow-up, optional 2-year extension
- Key Inclusion Criteria
- Age 50-90, MMSE score 20-28, positive amyloid biomarkers
- Primary Endpoint
- Change in brain amyloid plaque deposition at Week 24
What is ABBV-916?
ABBV-916 is a new medication being studied for the treatment of early Alzheimer's disease. It is also known as a humanised IgG1 monoclonal antibody against N-terminally truncated pyroglutamate-3 AB. This may sound complicated, but let's break it down:
- Humanised: This means the antibody is designed to be similar to human antibodies, reducing the chance of the body rejecting it.
- IgG1: This is a type of antibody that our immune system naturally produces.
- Monoclonal antibody: This is a laboratory-made protein that can bind to specific substances in the body.
- Pyroglutamate-3 AB: This is a specific form of amyloid beta, a protein that builds up in the brains of people with Alzheimer's disease.
How Does ABBV-916 Work?
ABBV-916 is designed to target and remove a specific form of amyloid beta protein that accumulates in the brains of people with Alzheimer's disease. By reducing these harmful protein deposits, researchers hope to slow down or potentially stop the progression of early Alzheimer's disease.
Current Research on ABBV-916
ABBV-916 is currently being studied in a Phase 2 clinical trial. This means that after initial safety testing, researchers are now investigating how well the drug works and continue to monitor its safety in a larger group of people with early Alzheimer's disease.
The main goals of this study are:
- To evaluate the safety and tolerability of ABBV-916
- To measure how effectively ABBV-916 reduces amyloid plaques in the brain
- To understand how the body processes the drug (pharmacokinetics) and how the drug affects the body (pharmacodynamics)
Who Can Participate in the ABBV-916 Study?
The study is looking for participants who meet specific criteria, including:
- Adults aged 50 to 90 years old
- People with early Alzheimer's disease
- Individuals with an MMSE score (a test of cognitive function) between 20 and 28
- Those with evidence of amyloid plaques in their brain, as shown by special brain scans and blood tests
Some people may not be able to participate if they have certain health conditions or are taking specific medications. It's important to discuss with a healthcare provider to determine eligibility.
Study Design
The study is designed as a randomized, double-blind, placebo-controlled trial. This means:
- Randomized: Participants are randomly assigned to different groups.
- Double-blind: Neither the participants nor the researchers know who is receiving the actual drug or a placebo.
- Placebo-controlled: Some participants receive a placebo (a substance with no active drug) for comparison.
The study consists of several phases:
- A screening period of up to 60 days
- A 24-week treatment period where participants receive either ABBV-916 or a placebo
- A 16-week follow-up period
- An optional extension period of about 2 years
ABBV-916 is given as an intravenous (IV) injection once every four weeks during the treatment period.
Potential Benefits of ABBV-916
While it's important to note that ABBV-916 is still in the research phase and its benefits are not yet proven, the potential benefits being studied include:
- Reduction of amyloid plaques in the brain
- Potential slowing of Alzheimer's disease progression
- Possible improvement or stabilization of cognitive function
Safety Considerations
As with any medical study, there are potential risks and side effects. The researchers are carefully monitoring participants for any adverse effects. Some safety considerations include:
- Participants should not have planned surgeries during the study period
- People with a history of drug or alcohol abuse within the past 2 years are excluded
- Individuals with certain infections or immune system disorders cannot participate
It's crucial for potential participants to discuss all possible risks and benefits with their healthcare provider and the study team before deciding to participate in the trial.